BioTelemetry Inc

BioTelemetry Inc

  • Price (USD)71.97
  • Today's Change0.04 / 0.06%
  • Shares traded514.26k
  • 1 Year change+35.27%
  • Beta1.2621
Data delayed at least 15 minutes, as of Jan 22 2021 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

BioTelemetry, Inc. provides monitoring services and digital population health management in a healthcare setting, medical device manufacturing and centralized laboratory services for clinical research. The Company operates in three segments: Healthcare, Technology and Research. The Healthcare segment, operating as CardioNet, LLC and Heartcare Corporation of America, Inc., is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. The Research segment, operating as Cardiocore, LLC and VirtualScopics, Inc., is engaged in laboratory services that provide cardiac monitoring, imaging services, scientific consulting and data management services for drug, medical treatment and device trials. The Technology segment, operating as Braemar Manufacturing, LLC, Universal Medical, Inc. and BioTelemetry Belgium BVBA. and BioTelemetry Technology ApS, focuses on the manufacturing, engineering and development of noninvasive cardiac monitors for healthcare companies.

  • Revenue in USD (TTM)438.83m
  • Net income in USD17.68m
  • Incorporated2013
  • Employees1.70k
  • Location
    BioTelemetry Inc1000 Cedar Hollow RdMALVERN 19355-2300United StatesUSA
  • Phone+1 (610) 729-7000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.gobio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
New Frontier Health Corp625.78m-107.17m1.24bn3.43k--1.024,803.401.98-0.7292-0.72924.768.500.5232----182,708.60-9.59---10.36--32.39---18.33--1.15-1.220.2032-------3,073.61------
Surgery Partners Inc1.83bn-191.20m1.56bn6.90k--15.4035.180.852-3.93-3.6837.6110.410.357628.715.71265,072.50-0.70181.17-0.98881.6525.2029.93-1.962.841.431.140.6485--3.3835.3453.60--50.81--
Evolent Health Inc987.04m-520.82m1.61bn3.40k--2.51--1.63-6.15-6.1111.647.480.6356--11.46290,304.40-33.67-5.60-42.86-7.0931.1041.45-52.97-14.91---4.160.3034--34.98---470.21------
U.S. Physical Therapy, Inc.427.62m30.12m1.69bn5.40k56.046.3829.843.952.352.3533.3720.620.7498--8.0079,188.348.049.4913.0713.9022.5022.8710.738.95--49.020.029948.836.189.5888.3010.3214.5518.89
Pennant Group Inc372.48m7.93m1.77bn4.70k245.6519.74143.424.750.25530.255312.673.180.8836--11.2779,250.641.88--2.28--24.77--2.13----14.040.0077--18.34---83.77------
CorVel Corporation560.75m41.27m1.87bn3.82k46.259.2432.403.332.262.2630.6711.301.29--7.76146,638.309.5013.5214.0821.1120.8720.497.366.65----0.00---0.5903.752.6810.637.19--
Genetron Holdings Ltd - ADR60.71m-483.05m1.87bn663.00--2.20--30.78-16.35-16.352.029.610.30988.344.17---246.46---315.23--56.40---795.62--5.68-0.09160.0587--43.63---45.39------
Addus Homecare Corporation758.82m34.67m2.02bn5.00k58.713.9843.212.662.182.1847.6432.121.15--5.91151,703.505.285.366.066.6129.3027.034.573.32--20.960.1083--25.5815.7058.2816.63-2.61--
MEDNAX Inc2.22bn18.92m2.09bn5.17k105.152.5935.330.93890.2319-8.6526.699.410.5762--5.84430,338.000.49030.29040.56250.3204----0.8510.4587--2.540.6843--1.707.57-544.72--12.04--
Magellan Health Inc5.20bn49.33m2.45bn10.10k48.061.5314.350.47111.975.32206.5561.671.59116.436.41514,379.001.512.202.223.313.623.810.94950.96432.053.100.28890.00-2.1213.75128.02-6.78-0.6287--
BioTelemetry Inc438.83m17.68m2.47bn1.70k148.956.2237.925.630.48320.483212.0011.570.62128.156.79258,134.702.506.712.757.5361.7461.714.038.172.727.320.28540.009.9221.39-30.30--19.16--
Agape ATP Corp3.13m29.66k2.82bn--107,142.90490.165,230.44902.170.000070.000070.00830.01530.5385--6.91--0.5103--0.5644--73.43--0.9477--5.47--0.00--------------
Veracyte Inc112.68m-34.32m3.20bn354.00--7.55--28.38-0.6819-0.68192.217.310.31547.305.46318,296.60-9.61-24.13-10.04-27.6064.1663.71-30.46-33.0126.28-138.730.0018--30.8225.8145.22--6.37--
Accolade Inc155.57m-48.07m3.26bn1.24k--8.40--20.96-1.13-1.133.487.040.5801--18.14124,453.60-17.92---24.65--43.43---30.90-----9.560.00--39.76--9.08------
Option Care Health Inc2.95bn-41.73m3.66bn5.08k--3.6898.261.24-0.2371-0.237116.525.321.1217.188.97580,333.80-1.59-11.52-1.86-14.1222.8626.89-1.42-
Data as of Jan 22 2021. Currency figures normalised to BioTelemetry Inc's reporting currency: US Dollar USD

Institutional shareholders

58.57%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Sep 20204.85m14.15%
ArrowMark Colorado Holdings LLCas of 30 Sep 20204.46m13.01%
The Vanguard Group, Inc.as of 30 Sep 20203.61m10.51%
Credit Suisse Securities (USA) LLC (Broker)as of 30 Sep 20201.23m3.58%
Dimensional Fund Advisors LPas of 30 Sep 20201.14m3.32%
Credit Suisse Asset Management (Schweiz) AGas of 31 Dec 20201.08m3.14%
SSgA Funds Management, Inc.as of 30 Sep 20201.06m3.09%
Stephens Investment Management Group LLCas of 30 Sep 20201.05m3.06%
Millennium Management LLCas of 30 Sep 2020873.23k2.55%
Loomis, Sayles & Co. LPas of 30 Sep 2020746.41k2.18%
More ▼
Data from 30 Sep 2020 - 31 Dec 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.